Sorry, you need to enable JavaScript to visit this website.

XELJANZ / XELJANZ XR (tofacitinib) Drug Interactions

7 DRUG INTERACTIONS

Table 5 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR and instructions for preventing or managing them.

Table 5: Clinical Relevant Interactions Affecting XELJANZ and XELJANZ XR When Coadministered with Other Drugs
Strong CP3A4 Inhibitors (e.g., ketoconazole)
Clinical Impact Increased exposure to tofacitinib
Intervention Dosage adjustment of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole)
Clinical Impact Increased exposure to tofacitinib
Intervention Dosage adjustment of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Strong CYP3A4 Inducers (e.g., rifampin)
Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response
Intervention Coadministration with XELJANZ/XELJANZ XR is not recommended [see Clinical Pharmacology, Figure 3 (12.3)]
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Clinical Impact Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, or UC.
Intervention Coadministration with XELJANZ/XELJANZ XR is not recommended [see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]

What's New

No Current Announcements.

Search

Please enter your search term(s) for XELJANZ / XELJANZ XR